Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 83 results for colitis

  1. Natural history of progression to colorectal cancer in people at increased risk:- What is the natural history of progression to colorectal cancer in people with inflammatory bowel disease (IBD) or adenomas?

    cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Number CG118 Date issued

    Research recommendation
    Published
    9 June 2015

  2. Effectiveness of biomarkers for determining level of risk of colorectal cancer:- Which biomarkers, including epigenic and genetic markers, are predictors of colorectal cancer? How should these be used to improve risk stratification?

    cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Number CG118 Date issued

    Research recommendation
    Published
    9 June 2015

  3. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    11 February 2016
    View quality statements

    Sections for QS114

  4. Surveillance programmes for people at increased risk of colorectal cancer:- How effective are colonoscopic surveillance programmes in improving overall survival and cancer-related survival in people at increased risk of colorectal cancer?

    cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Number CG118 Date issued

    Research recommendation
    Published
    9 June 2015

  5. Faecal incontinence in adults: management (CG49)

    This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.

    Clinical guideline
    Published
    27 June 2007
    View recommendations

    Sections for CG49

  6. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

    Evidence summary
    Published
    17 January 2017

  7. In a mild-to-moderate first presentation or inflammatory exacerbation of proctitis that is resistant to standard treatment, what is the effectiveness of topical immunomodulators, such as tacrolimus, in achieving clinical remission and what is the most effective formulation (suppository/ointment)?

    Source guidance details Comes from guidance Ulcerative colitis: management Number NG130 Date issued May 2019

    Research recommendation
    Published
    25 October 2019

  8. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.

    Technology appraisal guidance
    Published
    1 February 2016
    View recommendations

    Sections for TA383

  9. Ulcerative colitis: management (CG166)

    This guidance has been updated and replaced by NICE guideline NG130.

    Clinical guideline
    Published
    26 June 2013

  10. Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)

    This evidence summary has been updated and replaced by NICE guideline NG130.

    Evidence summary
    Published
    16 June 2015

  11. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    Discontinued Reference number: GID-TA11244

    Technology appraisal guidance
    Discontinued

  12. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)

    NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .

    Medtech innovation briefing
    Published
    4 December 2017

  13. OSNA for colon cancer staging (MIB77)

    NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging

    Medtech innovation briefing
    Published
    24 August 2016

  14. Infliximab for subacute manifestations of ulcerative colitis (TA140)

    This guidance has been updated and replaced by NICE technology appraisal guidance 329.

    Technology appraisal guidance
    Published
    23 April 2008

  15. Moderately to severely active ulcerative colitis: adalimumab (ESNM6)

    This evidence summary has been replaced by NICE technology appraisal guidance 329.

    Evidence summary
    Published
    2 November 2012